Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism

Acta Eur Fertil. 1994 Sep-Oct;25(5):303-6.

Abstract

Twenty-five women presenting moderate-severe PCOS-dependant hirsuitism were treated for 6 months with GnRH-A (Group A) or pill-combined and GnRH (Group B). Both therapeutic regimens significantly decreased androgen plasma levels. Hair diameter reduced in Group A by 22-34% and in Group B by 25-35%, while hirsuitism score respectively decreased by 22 and 24%. Clinical results, overlapping in the two groups, prove that GnRH-A are active in hirsuitism. Side effects, however, especially a decreased bone density (3.9%) in Group A make it necessary an association with oral contraceptive.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Androgens / blood
  • Bone Density / drug effects
  • Contraceptives, Oral, Combined / administration & dosage
  • Cyproterone Acetate / administration & dosage
  • Ethinyl Estradiol / administration & dosage
  • Female
  • Follicle Stimulating Hormone / blood
  • Hair / growth & development
  • Hirsutism / blood
  • Hirsutism / drug therapy*
  • Hirsutism / etiology
  • Humans
  • Leuprolide / adverse effects
  • Leuprolide / pharmacology
  • Leuprolide / therapeutic use*
  • Luteinizing Hormone / blood
  • Polycystic Ovary Syndrome / complications
  • Prolactin / blood
  • Severity of Illness Index
  • Sex Hormone-Binding Globulin / analysis

Substances

  • Androgens
  • Contraceptives, Oral, Combined
  • Sex Hormone-Binding Globulin
  • Ethinyl Estradiol
  • Cyproterone Acetate
  • Prolactin
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Leuprolide